Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
Wake
B
B
Department of Public Health and Epidemiology, University of Birmingham, UK.
Hyde
C
C
Bryan
S
S
Barton
P
P
Song
F
F
Fry-Smith
A
A
Davenport
C
C
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D009367:Neoplasm Staging; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012106:Research / Q000639:trends; D000069283:Rituximab; D016019:Survival Analysis; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab